EHang Holdings Ltd - ADR vs Humana Inc — how do they compare? EHang Holdings Ltd - ADR trades at $4.17 (market cap $309.45M), while Humana Inc trades at $433 (market cap $46.49B). The key difference: Humana Inc is far larger — about 150.2× EHang Holdings Ltd - ADR's market cap, and Humana Inc pays a 0.91% dividend while EHang Holdings Ltd - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold EHang Holdings Ltd - ADR for 47 Days and Humana Inc for 51 Days on average.
| EH | HUM | |
|---|---|---|
Market Cap | $309.45M | $46.49B |
Volume | 765,799 | 2,567,704 |
Sector | Industrials | Health |
52-Week High | $18.94 | $409.85 |
52-Week Low | $4.03 | $163.67 |
Typical Hold Time | 47 Days | 51 Days |
Enterprise Value | $261.14M | $53.84B |
Dividend Yield | — | 0.91% |
Signals from Pluang's Aura AI — not financial advice
EHang Holdings (EH) trades at $4.19, up 1.21% with bearish technical signals despite recent earnings beats. The company shows mixed fundamentals with strong revenue growth from $44M in 2022 to $418M in 2025, but deep losses persist with a -66% net margin. Recent news includes regulatory investigations and international expansion into Vietnam, creating conflicting sentiment signals for investors.
Outlook remains challenging with significant execution risks and negative profitability, though the eVTOL market offers long-term potential. The stock faces headwinds from regulatory scrutiny and cash burn, requiring careful risk assessment despite trading near technical support levels.
Humana (HUM) trades at $431.03, up 8.71% over the past day, reflecting strong momentum following a Barclays upgrade and positive earnings beats. The stock exhibits a bullish technical trend, with support at $378 and resistance at $394. Revenue has grown steadily from $92.9B in 2022 to $129.7B in 2025, though net income margins have compressed to 0.88%. Analyst consensus is a Buy with a $457.05 price target, and recent news highlights corporate initiatives and institutional investments.
The outlook for HUM is cautiously optimistic, driven by revenue growth and analyst support, but risks include margin pressure and regulatory scrutiny. Investment opportunity lies in execution of Medicare Advantage strategies, while key risks involve competitive pressures and potential fiduciary concerns highlighted in recent shareholder notices.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →